Contact

News

News and presentations

Press releases, conference data and company news since our founding in 2019.

Press releases

  1. Press releases

    Tacalyx secures €11 million to advance lead TACA-targeting ADC programme toward the clinic

    €11 million from the existing syndicate in a first closing of the seed extension. TCX-201 is selected as first clinical candidate, with a CTA filing planned for 2027.

  2. Press releases

    Tacalyx appoints Jean Engela as Chief Executive Officer to spearhead next phase of growth

    The former CEO of ADC company NBE Therapeutics takes over from co-founder Dr. Peter Sondermann, who continues as Chief Scientific Officer.

    Jean Engela, CEO, next to a quote on leading Tacalyx toward becoming a clinical-stage biotech company
  3. Press releases

    Tacalyx extends seed round to over €14 million

    New investor Thuja Capital leads the extension; Evan Castiglia joins the Board of Directors.

    Peter Sondermann, then CEO of Tacalyx, next to a quote on the seed extension to over 14 million euros
  4. Press releases

    Tacalyx and Leiden University Medical Center join forces to target tumor-specific glycans in colorectal cancer

    A €500k Health~Holland grant funds a collaboration with Prof. Manfred Wuhrer's team on the O-glycome of colorectal cancer.

  5. Press releases

    Tacalyx raises €7 million in seed funding to generate first-in-class anti-TACA antibodies for cancer treatment

    The Max Planck spin-out launches with a syndicate co-led by Boehringer Ingelheim Venture Fund and Kurma Partners.

Media inquiries: contact